Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M

Guardant Health, Inc.

2023-Q1 EPS reported -$1.30 revenue$128,714,000

Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).
Net loss $133.5M ($1.30/share) vs $123.2M ($1.21) prior year; non-GAAP net loss $108.5M ($1.06).
Gross margin 59% (down from 67%) on mix shift; operating expenses $209.7M (+12%).
FY2023 revenue guidance raised to $535-545M (prev $525-540M); expects FCF outflow ~$350M.
Appointed Ines Dahne-Steuber COO and promoted Darya Chudova CTO; Shield CRC screening PMA under FDA review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the fiscal quarter and year ended March 31, 2023 results: revenue $128.7 million, net income Net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.

Period: the fiscal quarter and year ended March 31, 2023
Revenue: $128.7 million
Net income: Net loss was $133.5 million
EPS: Net loss per share was $1.30
Guidance: raised
Result: reported results

Exact text from the filing

tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the quarter ended March 31, 2023 results: revenue $128.7 million, net income net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.

Period: the quarter ended March 31, 2023
Revenue: $128.7 million
Net income: net loss was $133.5 million
EPS: Net loss per share was $1.30
Guidance: raised
Result: reported results

Exact text from the filing

tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-23-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.